WO2007043294A1 - 内臓脂肪蓄積抑制剤 - Google Patents
内臓脂肪蓄積抑制剤 Download PDFInfo
- Publication number
- WO2007043294A1 WO2007043294A1 PCT/JP2006/318686 JP2006318686W WO2007043294A1 WO 2007043294 A1 WO2007043294 A1 WO 2007043294A1 JP 2006318686 W JP2006318686 W JP 2006318686W WO 2007043294 A1 WO2007043294 A1 WO 2007043294A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- visceral fat
- fat accumulation
- compound
- alkyl group
- group
- Prior art date
Links
- 210000001596 intra-abdominal fat Anatomy 0.000 title claims description 117
- 238000009825 accumulation Methods 0.000 title claims description 88
- 239000003112 inhibitor Substances 0.000 title claims description 41
- 150000001875 compounds Chemical class 0.000 claims abstract description 95
- 235000013305 food Nutrition 0.000 claims abstract description 45
- 239000000284 extract Substances 0.000 claims abstract description 39
- 239000004480 active ingredient Substances 0.000 claims abstract description 23
- 239000003960 organic solvent Substances 0.000 claims abstract description 15
- 241000234280 Liliaceae Species 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- IYIFZADLIMVECH-QYQNSBOUSA-N (9r,10s,13r,14r,17r)-17-[(2r,5r)-5-ethyl-6-methylheptan-2-yl]-4,10,13-trimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound CC1C(O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CCC21 IYIFZADLIMVECH-QYQNSBOUSA-N 0.000 claims description 7
- IYIFZADLIMVECH-UHFFFAOYSA-N 4-methylstigmast-7-en-3-ol Natural products CC1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CCC21 IYIFZADLIMVECH-UHFFFAOYSA-N 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 claims description 6
- AOQRDALGACAKHI-KVCRWQBISA-N (9r,10s,13r,14r,17r)-17-[(2r,5s)-5,6-dimethylheptan-2-yl]-4,10,13-trimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound CC1C(O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC[C@H](C)C(C)C)CC[C@H]33)C)C3=CCC21 AOQRDALGACAKHI-KVCRWQBISA-N 0.000 claims description 5
- AOQRDALGACAKHI-UHFFFAOYSA-N 4-methylergost-7-en-3-ol Natural products CC1C(O)CCC2(C)C(CCC3(C(C(C)CCC(C)C(C)C)CCC33)C)C3=CCC21 AOQRDALGACAKHI-UHFFFAOYSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims 4
- BYFVQXNAZAPZAR-JQZYULIUSA-N (8S,9S,10R,13R,14S,17R)-17-[(2R,5S)-5,6-dimethylhept-6-en-2-yl]-4,10,13-trimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol Chemical compound CC1C2CC[C@H]3[C@@H]4CC[C@H]([C@@H](CC[C@@H](C(=C)C)C)C)[C@]4(CC[C@@H]3[C@]2(CCC1O)C)C BYFVQXNAZAPZAR-JQZYULIUSA-N 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 abstract description 16
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract description 15
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract description 15
- 210000000683 abdominal cavity Anatomy 0.000 abstract description 6
- LMYZQUNLYGJIHI-SPONXPENSA-N 4alpha-methyl-5alpha-cholest-7-en-3beta-ol Chemical group C[C@@H]1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC[C@H]21 LMYZQUNLYGJIHI-SPONXPENSA-N 0.000 abstract description 5
- 235000013361 beverage Nutrition 0.000 abstract description 4
- 208000004611 Abdominal Obesity Diseases 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 50
- 238000012360 testing method Methods 0.000 description 44
- 230000000694 effects Effects 0.000 description 35
- 208000008589 Obesity Diseases 0.000 description 34
- 235000020824 obesity Nutrition 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 201000010099 disease Diseases 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 239000003814 drug Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 15
- 235000011399 aloe vera Nutrition 0.000 description 13
- 230000036541 health Effects 0.000 description 13
- 238000002372 labelling Methods 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 210000000577 adipose tissue Anatomy 0.000 description 10
- 235000019786 weight gain Nutrition 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 235000002961 Aloe barbadensis Nutrition 0.000 description 7
- 244000186892 Aloe vera Species 0.000 description 7
- 230000004584 weight gain Effects 0.000 description 7
- 241001116389 Aloe Species 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- -1 cholestenone compound Chemical class 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- LMYZQUNLYGJIHI-UHFFFAOYSA-N Methostenol Natural products CC1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CCC21 LMYZQUNLYGJIHI-UHFFFAOYSA-N 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 210000001624 hip Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000013293 zucker diabetic fatty rat Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- NYOXRYYXRWJDKP-GYKMGIIDSA-N cholest-4-en-3-one Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 NYOXRYYXRWJDKP-GYKMGIIDSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000020805 dietary restrictions Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000003918 fraction a Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 235000002378 plant sterols Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 240000007474 Aloe arborescens Species 0.000 description 2
- 235000004509 Aloe arborescens Nutrition 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229940069521 aloe extract Drugs 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 2
- 235000000431 campesterol Nutrition 0.000 description 2
- NYOXRYYXRWJDKP-UHFFFAOYSA-N cholestenone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 NYOXRYYXRWJDKP-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012156 elution solvent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 210000002196 fr. b Anatomy 0.000 description 2
- 210000000540 fraction c Anatomy 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000006371 metabolic abnormality Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000009925 nephrosclerosis Diseases 0.000 description 2
- 238000012924 normal-phase thin-layer chromatography Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 238000004238 reversed phase thin layer chromatography Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- PUGBZUWUTZUUCP-ICUQLCECSA-N (9r,10s,13r,14r,17r)-17-[(2r,5s)-5,6-dimethylheptan-2-yl]-10,13-dimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1C(O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC[C@H](C)C(C)C)CC[C@H]33)C)C3=CCC21 PUGBZUWUTZUUCP-ICUQLCECSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 241001073152 Aloe africana Species 0.000 description 1
- 244000101643 Aloe ferox Species 0.000 description 1
- 235000015858 Aloe ferox Nutrition 0.000 description 1
- 241000782139 Aloe spicata Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000027796 Blood pressure disease Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012665 Diabetic gangrene Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- YSKVBPGQYRAUQO-UZSYLJJSSA-N Schottenol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 YSKVBPGQYRAUQO-UZSYLJJSSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- HJPOKQICBCJGHE-UHFFFAOYSA-J [C+4].[Cl-].[Cl-].[Cl-].[Cl-] Chemical compound [C+4].[Cl-].[Cl-].[Cl-].[Cl-] HJPOKQICBCJGHE-UHFFFAOYSA-J 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Definitions
- Mitsuru means that the excess of () in the body and the excessive consumption of mosquitoes due to lack of exercise, etc., means that the body has () accumulated excessively. It has been pointed out that it will be the board.
- the 000 4 tissue has a subcutaneous body that accumulates under the skin and a viscera that accumulates in the viscera of the internal organs. It is known that there is a subcutaneous filling and a visceral filling, and in particular, the product of visceral fat strongly affects the complication and severity of obesity in obesity.
- the genus A is known as a typical plant such as Abella (Aoebabadens sM e), Chia (Aoe abo escenM e Va a aens sBe ge), and it is reported that they are effective. Among them, it is disclosed that there is a full effect on the output of A (6 is disclosed. 7), which includes the following as a sense for the weight section (8), respectively. Furthermore, it was reported that when administered to Chia, the body weight decreased significantly in the concentration (
- the active ingredient described in Patent 6 is an extract, but is associated with weight gain.
- the other purpose of Ming is
- the present invention which solves the above-mentioned problems, is a visceral control agent containing the following () as an active ingredient.
- RR 0020 is an achi having an atomic number of 5 to 6 or having the form of or, 2 or 2, or an achi-substituted a group containing a group and / or a carboxy group, and 2 R 3 is a hydrogen atom , Is an achi or substituted achi group having from 3 to 3 carbon atoms, and 4 forms CO together with the ring-constituting elementary atoms, or is a deviation of O OCOC.
- ) 2 3 is a hydrogen atom, the other is a methyl group, and 4 is a hydroxyl group,
- Ra Rb is the deviation of H OH or CH.
- R Rd is one of H OH CH. 002 3) 2) is the same as 4
- RR 002 is an achi having a number of elementary atoms of 5 to 6, two or two, or an achi-substituted a group containing a group and / or a carboxy group
- 2 R3 is a hydrogen atom
- a Rb is a deviation of H OH or CH3.
- R is a deviation of H OH or CH. ) 003 2 7) 6) is the same as 4
- the food should be the one shown in () above.
- the substance indicated by () in the description for the preparation of the visceral control agent the substance having at least a small amount of the substance, the substance having the hot water, or these substances It is for
- a method of suppressing visceral fat according to the fifth aspect of the present invention which solves the problem, wherein the product, hot water product, or product shown in () above, which has at least a small amount of
- the method is characterized by administering these to a subject who wants to suppress visceral fat.
- the active ingredient of the clear drug can be experimentally safe and easily available, for example, it can be easily produced from avera (Aoebabadens sM e).
- the substance is an active substance of 004 Akira, which is an active ingredient, but it can be determined within a range having an action of suppressing visceral fat. 004 Also, it is used as an active ingredient of Akira's agent (below, Akira's blade has a dry amount of
- dryness in Ming is the mass determined after the substance is deposited according to the method generally defined in the 14th Pharmacopoeia (Ministry of the 3 3 It is possible to determine by taking the compound, releasing it with C 4, releasing it in the scale, and measuring the amount with a scale.
- 004 () is an ortho group having 5 to 6 elementary atoms, or two or two groups. These acryl groups may be substituted acryl or substituted acryl groups in which at least at least one atom has been replaced with a radical and / or a carboxylic group.
- 2 and 3 are a hydrogen atom, an achi having 3 to 3 carbon atoms, or a substituted achi group, and 4 forms C 2 O together with the ring-constituting atom, or is a deviation of O 2 OCOC.
- achi having 3 to 3 elementary atoms methyl and chi are preferred, and methyl group is particularly preferred.
- 004 is preferably a deviation of the groups shown below.
- Ra Rb is either H OH or CH.
- CH CH CH R CH CH Rd where Rd is H, OH, or CH3.
- one of the 23 is a hydrogen atom and the other is a methyl group.
- 4 is a hydroxyl group.
- R23 is a hydrogen atom, the other is a methyl group, and 4 is a hydroxyl group, which is represented by the above () (where, Rd is C).
- 4 is a hydrogen atom, the other is a methyl group, 4 is a hydroxyl group, and is represented by the above-mentioned ().
- 4 methyl ester 7 3o in the above (), 2 3 is a hydrogen atom, the other is a methyl group, 4 is a hydroxyl group, and is represented by the above It is a base.
- the food and drink of Akira Myo may include the above-mentioned species alone or may include any of the above.
- a method normally used for delivery can be used.
- organic to 3 is used, while heating and flowing at a temperature below the point of, and supersonic waves are generated at room temperature.
- the effluent can be separated from the insoluble matter by an appropriate method such as centrifugation to obtain the effluent.
- the product can be purified by various types of chromatography, for example, Kage Karakuto.
- Kage-karactoglyme when using chrome methano as, the compound of the present invention is eluted at 25 deg of chrome methano.
- xanthi (4) as, the light compound is eluted as the first fraction.
- the downloaded area can be further accessed using a PC, etc.
- It may also be produced by obvious synthetic methods, or biological methods using microbial enzymes, and enzymatic methods.
- 006 has the effect of suppressing visceral fat, and as a result can prevent visceral fullness. Therefore, it can be used for visceral control or as an active ingredient of food and drink.
- a) contains an insulin-lowering substance, which is considered to be preferable as a food or drink that does not expect a lowering action. Therefore, it is preferable that these components are included, including those of Ming. In addition, it can be used as an active ingredient of a visceral control agent.
- 006 has a clear effect of suppressing visceral fat, and as a result, can prevent visceral fullness. Therefore, it can be used as it is as the active ingredient of the clear drug or food containing it.
- plant products or hot water products including the products of Minghu, may use these (hereinafter referred to as products) or as an active ingredient of food and drink.
- products plant products or hot water products, including the products of Minghu
- the above-mentioned product or product contained in the drug is contained in a dry amount of at least, more preferably, ..., and particularly preferably, 5 or more.
- the above-mentioned products and foods contained in foods and drinks should be at least dry.
- the level is ..., more preferably, the level 5 is particularly preferable. It may be two items higher than the gift. Also, the above-mentioned product may be It can also be used as is.
- the 006 Ming agent can be administered orally or as a non-containing product, as it is, or as a combination of these products with a pharmaceutically acceptable preparation.
- the salt of the Ming agent can be used as the Ming agent. It includes those with metal () organics, and these strikes are listed in Rem ng on s Ph mace ca cences, 7, 48, 985. These are illustrated.
- organic acid salts such as acid salts, acid salts, acid salts, di-, and oxalates, acid salts, acid salts, tartrate salts, acid salts, acid salts, acid salts, lactates, methanates.
- Organic salts such as hong salt, tonson salt, salt, satin salt, and stearin salt are regularly included. It can also be a metal such as sodium, potassium, um, magnesium, or aluminium, or an anode such as gin.
- the above-mentioned substances and water of salt contained therein are also included in the present invention.
- the state of the drug is not particularly limited and may be therapeutically appropriate. Specific examples include a drug, a pill, a powder, a drug, a suspension, an emulsion, a cuff, a cap, an injection ,,, an eye drop, and a dot.
- the commonly used formulations can be used, such as binders, disintegrants, lubricants, stabilizers, pastes, diluents, and injections.
- it may be used in combination with a product containing it and another drug for internal production.
- the amount of the product contained in the Akira compound is not particularly limited, and it may be selected, for example, as a product of the Akira compound, at least in the drug product. , Especially preferred ⁇ 5 ⁇ .
- the agent is preferably used for treatment of a person with a visceral healthy person who is in a state of accumulation.
- the anti-mycotic agent can prevent the diseases caused by visceral fat, complications such as, for example, and reduce these complications.
- diseases caused by internal organs include obesity, particularly internal organs, diseases, urinary diseases, hypertension, and arteriosclerosis.
- the complications resulting from these are urinary illness due to urinary illness, nerve damage, urinary illness, stroke due to hypertension, dysfunction, and vascular disease such as stroke and cerebral due to arteriosclerosis, heart attack, Illness, failure, etc. can be exemplified.
- the things of Ming are Gubin. It has been found that it has the effect of lowering the value and improving high blood sugar (external publication 25 94838). It is preferable that the brightening agent is applied and that the gubin value is not higher than that of a healthy person.
- the clear control agents are also useful for preventing metabolic syndrome.
- the suppression or reduction of visceral fat is associated with metabolic syndrome and associated arterial stiffness, illness, and urinary disease and hypertension, which are pointed out as squaters. It is extremely effective in preventing the associated complications.
- Bokdomdom in Ming is a pathological condition observed in the group of the symptoms of chips, that is, infectious disease or hyperglycemia,
- the period of the meikai drug is not particularly limited, and the period can be selected according to the treatment method of the target disease. In addition, it is preferable to make a decision according to the administration preparation, the age and sex of the patient, other conditions, and the condition of the patient. It is selected according to the usage, dosage, age of the patient, sex, degree of illness, and other conditions of the clear medicine.
- the amount of the bright substance as an active ingredient is: ⁇ ⁇ 5, and preferably, ⁇ ⁇ It is good to use the amount in the day as a guide. In addition, when using a product containing a clear product, it is a good idea to use an amount such that the extract is ⁇ OO, preferably ⁇ O. Even if there is a gap, it can be given in multiple doses.
- the food is not particularly limited in form and shape as long as it can be taken orally without impairing the effects of the above-mentioned active ingredients, and it contains the above-mentioned active ingredients and is prepared by a conventional method using raw materials usually used in foods. Can be manufactured by.
- the amount of the foods, etc., that are contained in the Myo foods may be selected without any particular limitation.For example, as the Myo foods, the amount of foods and drinks may be at least.
- the Akira food is useful for the prevention of diseases caused by visceral fat, such as illness. It can also be used to prevent the development of internal organs such as a box bomb. Furthermore, the food of Myo can prevent the complications caused by the internal organs and reduce these complications, as well as the case of Myo.
- the food of Ming is labeled with a label indicating that it is used for visceral control, for example, a food containing a product with visceral fruits labeled as, or a plant product labeled with It is preferable to sell it as a food containing Since the compound of the present invention has a purpose for producing viscera including it, it is considered that the regulation of food and drink also has the meaning of improving the visceral content. Therefore, the food of Ming can be labeled as good use. That is, the above is this
- the wording used to make the above indication is not limited to or, but is also a good-mattering word.Even in other words, the effect of suppressing visceral fat or preventing or improving visceral fullness. If it is a word that expresses, it is not included in the box of Ming. As a wording, for example, it is possible to make a display based on the way to recognize the result of visceral and visceral goodness with respect to demand. For example, it is possible to exemplify the indication of factors such as metabolic factors that are suitable for those who have begun to become concerned about the waste and those who have an orientation (low and low). .
- 0076 means to inform the above-mentioned way to the demand, and if the above-mentioned way is recalled / displayed, it does not matter whether it is the display target, the display target or the display target. It is all clear.
- the demand can be expressed in a way that the above situation can be directly recognized. . Physically speaking, the act of stating the above in the package of the merchandise related to the food of Myo, the transfer of the item stating the above in the package of the merchandise, transfer, exhibition for transfer, and importation Acts, advertisements regarding products, prices, etc. with the above mentioned in the trade, and displayed, or with the above mentioned in the information containing them, by the electromagnetic (Internet etc.) method. The actions provided and the like can be illustrated.
- the label is a label approved by the government (for example, it is licensed based on various systems established by the government, and it is based on that), especially packaging and containers. It is preferable to advertise on the sales floors, such as catalogs, catalogs, OPs, and other documents.
- Examples include labeling for products and pharmaceuticals, and labeling approved by the Ministry of Labor, such as labeling approved by specified foods and similar systems.
- the person can be designated as a specific food, designated as a conditional specific food, labeled that it affects the body's structure and function, and diseased.
- 4 3 Labels as specified foods (particularly in the case of health care) and similar items specified by the Ordinance of the Ministry of Labor of Japan 86) can be listed as typical examples.
- the titano extract was 35, which was obtained by decompressing this titano.
- the eluent was separated by stepwise gradient method in which the degree of methano was increased stepwise. It was confirmed by facies and kutgray (Mek, Kage 6 254 P 8 2543) that there are clear compounds in the clones that were released in Kumumethano 25 of these clones.
- Z (Z cke Dabe cFa) rat which is an obesity and urine disease product, was used to study the production of a substance having a nocturnal character. 008 () of charge
- test sample 4 4 meth. 7 3 o
- test sample 2 4 meth- tern 7 3
- 5 4 meth ist 7 3 o
- test sample Male Z rats (purchased from Chas) were bred using (Satite Dit) and then bred to 6 rats. Oral administration of the samples, test sample, test sample 2, test sample 2, test sample 22, test sample 3, test sample 3 2 to rat 4 for 4 consecutive days for 44 days. did. 45 days after the start, the amount was measured as an internal organ.
- the table shows the amount in 45 days from the beginning. Samples Compared to rat (6 83 O), the test sample with the degree of substance being O, the test sample 2 and the test sample 3 were 4, 48 34, 3, 78 26, 3, 36 67, respectively. The results of visceral fat were confirmed, showing 65 54 9 and 48 7. On the other hand, in Test sample 2, Test sample 2 2 and Test sample 32, which showed different physical properties, the deviation also tended to decrease, but no significant effect was observed. No pathological findings were observed during the administration. Note that P in the table shows the significance rate by T ke a e s es.
- test sample 2 and test sample 3 were used as test samples.
- a solution containing no sample was used as the sample.
- test sample After raising male Z rats (purchased from Yasu) using (Satchite), their weight was measured, and 6 rats were placed.
- the test sample, test sample 2 test sample 3, and the solution of the sample were orally administered to rats every day for 44 days at a body weight of 4.
- the weight of the rats was measured 42 days after the start, and the difference from the body weight before administration was increased.
- the weight of the food consumed during the day was measured once a week from the day of administration, and this average value was defined as per day.
- Table 2 shows the interval between 42 per rat. No significant increase or decrease was observed in the groups administered with the test sample, test sample 2, and test sample 3 as compared with the group administered with the sample. The (heavy) dose was almost the same as when the sample was administered. Have a nostalgia , It was found that it did not affect the increase of food intake and weight of rats. 00902 (
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06798178.7A EP1927360B1 (en) | 2005-09-22 | 2006-09-21 | Agent for inhibiting visceral fat accumulation |
CA2611181A CA2611181C (en) | 2005-09-22 | 2006-09-21 | Agent for inhibiting visceral fat accumulation |
ES06798178.7T ES2449744T3 (es) | 2005-09-22 | 2006-09-21 | Agente para inhibir la acumulación de grasa visceral |
CN2006800236573A CN101212976B (zh) | 2005-09-22 | 2006-09-21 | 内脏脂肪蓄积抑制剂 |
JP2007539844A JP4164538B2 (ja) | 2005-09-22 | 2006-09-21 | 内臓脂肪蓄積抑制剤 |
US11/913,758 US8093233B2 (en) | 2005-09-22 | 2006-09-21 | Agent for inhibiting visceral fat accumulation |
AU2006300629A AU2006300629B2 (en) | 2005-09-22 | 2006-09-21 | Agent for inhibiting Visceral fat accumulation |
HK08111297.9A HK1119403A1 (en) | 2005-09-22 | 2008-10-13 | Visceral fat accumulation inhibitor |
US12/841,076 US8518924B2 (en) | 2005-09-22 | 2010-07-21 | Agent for inhibiting visceral fat accumulation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005275172 | 2005-09-22 | ||
JP2005-275172 | 2005-09-22 | ||
JP2005-287888 | 2005-09-30 | ||
JP2005287888 | 2005-09-30 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/913,758 A-371-Of-International US8093233B2 (en) | 2005-09-22 | 2006-09-21 | Agent for inhibiting visceral fat accumulation |
US12/841,076 Continuation US8518924B2 (en) | 2005-09-22 | 2010-07-21 | Agent for inhibiting visceral fat accumulation |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007043294A1 true WO2007043294A1 (ja) | 2007-04-19 |
WO2007043294A9 WO2007043294A9 (ja) | 2007-06-14 |
Family
ID=37942546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/318686 WO2007043294A1 (ja) | 2005-09-22 | 2006-09-21 | 内臓脂肪蓄積抑制剤 |
Country Status (11)
Country | Link |
---|---|
US (2) | US8093233B2 (ja) |
EP (1) | EP1927360B1 (ja) |
JP (1) | JP4164538B2 (ja) |
KR (1) | KR100935813B1 (ja) |
CN (2) | CN101804144A (ja) |
AU (1) | AU2006300629B2 (ja) |
CA (1) | CA2611181C (ja) |
ES (1) | ES2449744T3 (ja) |
HK (1) | HK1119403A1 (ja) |
RU (1) | RU2419438C2 (ja) |
WO (1) | WO2007043294A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010058795A1 (ja) | 2008-11-19 | 2010-05-27 | 森永乳業株式会社 | 抗酸化剤 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2611086C (en) * | 2005-09-22 | 2011-06-21 | Morinaga Milk Industry Co., Ltd. | Agent for inhibiting visceral fat accumulation |
EP2377875B1 (en) * | 2008-11-19 | 2020-09-02 | Morinaga Milk Industry Co., Ltd. | Antioxidant |
EP3225242A4 (en) * | 2014-11-28 | 2018-08-15 | Morinaga Milk Industry Co., Ltd. | Matrix metalloproteinase production inhibitor |
CN111491524A (zh) * | 2017-12-19 | 2020-08-04 | 森永乳业株式会社 | 芦荟粉末的制造方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1036283A (ja) * | 1996-07-18 | 1998-02-10 | Ichimaru Pharcos Co Ltd | 線維芽細胞増殖促進剤 |
JP2000319190A (ja) * | 1999-05-10 | 2000-11-21 | Nonogawa Shoji Kk | 肥満の予防改善剤 |
JP2003286185A (ja) * | 2002-03-29 | 2003-10-07 | Daily Foods Kk | アロエベラ圧搾液及び該圧搾液を有効成分とする血糖値降下剤 |
WO2004105770A1 (en) * | 2003-05-31 | 2004-12-09 | Forbes Medi-Tech Inc. | Composition comprising one or more phytosterols and/or phytostanols and glucomannan and uses of the composition in treating lipid disorders in individuals with and without type ii diabetes |
WO2005094838A1 (ja) * | 2004-03-31 | 2005-10-13 | Morinaga Milk Industry Co., Ltd. | 高血糖改善のための医薬及び飲食品 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4851224A (en) * | 1986-06-05 | 1989-07-25 | Carrington Laboratories, Inc. | Process for preparation of aloe products |
US4841224A (en) | 1987-11-10 | 1989-06-20 | Washington Technology Center | Gap width probe and method |
JP3029907B2 (ja) | 1991-12-20 | 2000-04-10 | 理化学研究所 | 抗肥満剤 |
FR2706454B1 (fr) | 1993-06-17 | 1995-09-15 | Roussel Uclaf | Nouveaux 19-Nor stéroïdes, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les contenant. |
JP3862295B2 (ja) | 1993-09-30 | 2006-12-27 | 独立行政法人理化学研究所 | 抗肥満剤 |
GB9704904D0 (en) | 1997-03-10 | 1997-04-30 | Riley Fletcher Foundation The | Essential oil composition |
JP3873097B2 (ja) | 1997-11-06 | 2007-01-24 | 独立行政法人理化学研究所 | 抗肥満剤及び脂質代謝改善剤 |
NZ330439A (en) | 1998-05-15 | 2001-01-26 | Immuno Lab Ltd | Dietary supplements comprising collagen hydrosylate, aloe vera, hydroxy citric acid, L-carnitine and water for weight loss |
US6506387B1 (en) | 1999-04-28 | 2003-01-14 | Paxa N.V. | Method for preparing aloin by extraction |
JP3858055B2 (ja) | 2000-02-29 | 2006-12-13 | 独立行政法人理化学研究所 | 抗肥満剤及び脂質代謝改善剤 |
IN188857B (ja) | 2000-07-14 | 2002-11-16 | Govind Kane Dr Shantaram | |
FR2811984B1 (fr) * | 2000-07-19 | 2004-02-06 | Pharmascience Lab | Procede de preparation d'un ester de corps gras et son utilisation dans les domaines pharmaceutique, cosmetique ou alimentaire |
RU2192876C2 (ru) | 2001-01-30 | 2002-11-20 | Савина Лидия Васильевна | Способ снижения уровня липидов |
CN1426702A (zh) * | 2001-12-21 | 2003-07-02 | 游绍裘 | 一种维持肠道健康、协助消减腹部肥胖的保健食品 |
JP2005015425A (ja) | 2003-06-27 | 2005-01-20 | Kao Corp | 脂質代謝改善剤 |
-
2006
- 2006-09-21 CN CN201010164375A patent/CN101804144A/zh active Pending
- 2006-09-21 US US11/913,758 patent/US8093233B2/en active Active
- 2006-09-21 CA CA2611181A patent/CA2611181C/en active Active
- 2006-09-21 AU AU2006300629A patent/AU2006300629B2/en active Active
- 2006-09-21 ES ES06798178.7T patent/ES2449744T3/es active Active
- 2006-09-21 KR KR1020077025775A patent/KR100935813B1/ko active IP Right Grant
- 2006-09-21 CN CN2006800236573A patent/CN101212976B/zh active Active
- 2006-09-21 RU RU2007146364/15A patent/RU2419438C2/ru not_active IP Right Cessation
- 2006-09-21 WO PCT/JP2006/318686 patent/WO2007043294A1/ja active Application Filing
- 2006-09-21 EP EP06798178.7A patent/EP1927360B1/en active Active
- 2006-09-21 JP JP2007539844A patent/JP4164538B2/ja active Active
-
2008
- 2008-10-13 HK HK08111297.9A patent/HK1119403A1/xx not_active IP Right Cessation
-
2010
- 2010-07-21 US US12/841,076 patent/US8518924B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1036283A (ja) * | 1996-07-18 | 1998-02-10 | Ichimaru Pharcos Co Ltd | 線維芽細胞増殖促進剤 |
JP2000319190A (ja) * | 1999-05-10 | 2000-11-21 | Nonogawa Shoji Kk | 肥満の予防改善剤 |
JP2003286185A (ja) * | 2002-03-29 | 2003-10-07 | Daily Foods Kk | アロエベラ圧搾液及び該圧搾液を有効成分とする血糖値降下剤 |
WO2004105770A1 (en) * | 2003-05-31 | 2004-12-09 | Forbes Medi-Tech Inc. | Composition comprising one or more phytosterols and/or phytostanols and glucomannan and uses of the composition in treating lipid disorders in individuals with and without type ii diabetes |
WO2005094838A1 (ja) * | 2004-03-31 | 2005-10-13 | Morinaga Milk Industry Co., Ltd. | 高血糖改善のための医薬及び飲食品 |
Non-Patent Citations (3)
Title |
---|
ITOH T. ET AL.: "Four new and other 4alpha-methylsterols in the seeds of Solanaceae", PHYTOCHEMISTRY, vol. 17, no. 5, 1978, pages 971 - 977, XP003011583 * |
See also references of EP1927360A1 * |
TANAKA M. ET AL.: "Identification of Five Phytosterols from Aloe Vera Gel as Anti-diabetic Compounds", BIOL. PHARM. BULL., vol. 26, no. 7, July 2006 (2006-07-01), pages 1418 - 1422, XP003011584 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010058795A1 (ja) | 2008-11-19 | 2010-05-27 | 森永乳業株式会社 | 抗酸化剤 |
US8470807B2 (en) | 2008-11-19 | 2013-06-25 | Morinaga Milk Industry Co., Ltd. | Antioxidant |
Also Published As
Publication number | Publication date |
---|---|
WO2007043294A9 (ja) | 2007-06-14 |
ES2449744T3 (es) | 2014-03-21 |
HK1119403A1 (en) | 2009-03-06 |
US20100286104A1 (en) | 2010-11-11 |
CN101804144A (zh) | 2010-08-18 |
EP1927360A4 (en) | 2010-09-29 |
KR20080011283A (ko) | 2008-02-01 |
CA2611181A1 (en) | 2007-04-19 |
CA2611181C (en) | 2010-11-02 |
AU2006300629A1 (en) | 2007-04-19 |
RU2419438C2 (ru) | 2011-05-27 |
KR100935813B1 (ko) | 2010-01-08 |
RU2007146364A (ru) | 2009-06-20 |
EP1927360A1 (en) | 2008-06-04 |
US8093233B2 (en) | 2012-01-10 |
AU2006300629B2 (en) | 2009-12-10 |
US8518924B2 (en) | 2013-08-27 |
JPWO2007043294A1 (ja) | 2009-04-16 |
CN101212976A (zh) | 2008-07-02 |
US20090093450A1 (en) | 2009-04-09 |
CN101212976B (zh) | 2010-12-29 |
JP4164538B2 (ja) | 2008-10-15 |
EP1927360B1 (en) | 2014-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8338403B2 (en) | Drug for improving hyperglycemia | |
WO2006035525A1 (ja) | 高血糖改善のための医薬及び飲食品 | |
WO2007043305A1 (ja) | インスリン抵抗性改善剤 | |
CA2616544C (en) | Agent for improving insulin resistance | |
US8518924B2 (en) | Agent for inhibiting visceral fat accumulation | |
WO2006123466A1 (ja) | 膵臓機能改善のための医薬又は飲食品 | |
KR20080016827A (ko) | 인슐린 저항성 개선제 | |
KR100941015B1 (ko) | 내장 지방 축적 억제제 | |
RU2315601C1 (ru) | Лекарственное средство и пищевой продукт или напиток для снижения гипергликемии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680023657.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007539844 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006798178 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4913/CHENP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11913758 Country of ref document: US Ref document number: 1020077025775 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006300629 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2611181 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007146364 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006300629 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |